| Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. A Keech, RJ Simes, P Barter, J Best, R Scott, MR Taskinen, P Forder, ... Lancet 366 (9500), 1849, 2005 | 4090 | 2005 |
| on behalf of the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study … A Keech, RJ Simes, P Barter, J Best, R Scott, MR Taskinen Lancet 366, 1849-61, 2005 | 2131* | 2005 |
| Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate … R Scott, R O'Brien, G Fulcher, C Pardy, M d'Emden, D Tse, MR Taskinen, ... Diabetes care 32 (3), 493-498, 2009 | 599 | 2009 |
| On behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a pre-specified analysis of a … K Rajamani, PG Colman, LP Li Lancet 373, 1780-8, 2009 | 409* | 2009 |
| Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. R Moses, R Slobodniuk, S Boyages, S Colagiuri, W Kidson, J Carter, ... Diabetes care 22 (1), 119-124, 1999 | 366 | 1999 |
| Acromegaly. Clinical and biochemical features in 500 patients. S Ezzat, MJ Forster, P Berchtold, DA Redelmeier, V Boerlin, AG Harris Medicine 73 (5), 233, 1994 | 337 | 1994 |
| The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults RC Cuneo, S Judd, JD Wallace, D Perry-Keene, H Burger, S Lim-Tio, ... The Journal of Clinical Endocrinology & Metabolism 83 (1), 107-116, 1998 | 330 | 1998 |
| GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety R Abs, BÅ Bengtsson, E Hernberg‐Ståhl, JP Monson, JP Tauber, P Wilton, ... Clinical Endocrinology 50 (6), 703-713, 1999 | 318 | 1999 |
| Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: Results of the International Multicenter Acromegaly Study Group ML Vance, AG Harris Archives of Internal Medicine 151 (8), 1573, 1991 | 306 | 1991 |
| Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group H Ag Arch Intern Med 151, 1573-1578, 1991 | 306 | 1991 |
| A systematic review of chronic disease management N Zwar, M Harris, R Griffiths, M Roland, S Dennis, G Powell Davies, ... Australian Primary Health Care Research Institute (APHCRI), 2006 | 278 | 2006 |
| Clinical review 49: iodine deficiency disorders SC Boyages The Journal of Clinical Endocrinology & Metabolism 77 (3), 587-591, 1993 | 271 | 1993 |
| Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology JR Burgess, P Tucker Thyroid 16 (1), 47-53, 2006 | 245 | 2006 |
| Relationship of Type 2 diabetes to the prevalence, incidence and progression of age‐related hearing loss P Mitchell, B Gopinath, CM McMahon, E Rochtchina, JJ Wang, ... Diabetic Medicine 26 (5), 483-488, 2009 | 216 | 2009 |
| Guideline: Calcium supplementation in pregnant women World Health Organization World Health Organization, 2013 | 190 | 2013 |
| Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants P Smerdely, SC Boyages, D Wu, G Leslie, E John, A Lim, K Waite, ... The Lancet 334 (8664), 661-664, 1989 | 172 | 1989 |
| Endemic goitre in central China caused by excessive iodine intake L Mu, Q Chengyi, Q Qidong, J Qingzhen, CJ Eastman, JK Collins, L Derun, ... The lancet 330 (8553), 257-259, 1987 | 167 | 1987 |
| Cochlear origin of hearing loss in MELAS syndrome CM Sue, LJ Lipsett, DS Crimmins, CST DipAud, SC Boyages, ... Annals of neurology 43 (3), 350-359, 1998 | 159 | 1998 |
| Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with … R Scott, R O’Brien, G Fulcher, C Pardy, M d’Emden, D Tse, MR Taskinen, ... Diabetes Care 32 (3), 493-8, 2009 | 155 | 2009 |
| Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators R Scott, R O'Brien, G Fulcher, C Pardy, M D'Emden, D Tse, MR Taskinen, ... Effects of fenofibrate treatment on cardiovascular disease risk in 9, 0 | 155* | |
NW CheungAustraliaGeverifieerd e-mailadres voor sydney.edu.au
